Affinia Therapeutics key facts
as of Oct 2026- Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles.
- Affinia Therapeutics is valued at approximately $145.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $210.0M across 3 recorded rounds; the latest was Early Stage VC ($13.3M) in Sep 2025.
- Notable investors include RA Capital Management, GV, Service Provider Capital, New Enterprise Associates, F-Prime Capital — 19 tracked in total.
- Affinia Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently May 2021 ($110.0M sold to 22 investors).
- Status: Privately Held (backing).
Valued at $145.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 19 names
- ·Watch Affinia Therapeutics: the Monday email on marks, rounds and moves
Affinia Therapeutics funding rounds
3 roundsWho backs Affinia Therapeutics
19+Affinia Therapeutics valuation
Affinia Therapeutics was valued at $145 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Affinia Therapeutics raised?
Affinia Therapeutics has raised $210 million across 3 recorded rounds since 2020. The largest was a $38.5 million early-stage round in Mar 2020; the most recent was a $13.3 million early-stage round in Sep 2025.
Affinia Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently in May 2021 ($110 million sold to 22 investors).
Affinia Therapeutics investors
19 investors are on record for Affinia Therapeutics, including RA Capital Management, GV, Service Provider Capital and New Enterprise Associates. By type, the record holds 5 venture capital firms, 5 hedge funds and 3 asset managers. The early-stage round in Sep 2025 drew 20 investors.
About Affinia Therapeutics
Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2019
- Employees
- 51
- Website
- affiniatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.